These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 32955874)

  • 1. Discovery of Small-Molecule Inhibitors of Receptor Activator of Nuclear Factor-κB Ligand with a Superior Therapeutic Index.
    Rinotas V; Papakyriakou A; Violitzi F; Papaneophytou C; Ouzouni MD; Alexiou P; Strongilos A; Couladouros E; Kontopidis G; Eliopoulos E; Douni E
    J Med Chem; 2020 Oct; 63(20):12043-12059. PubMed ID: 32955874
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cheminformatics-aided discovery of small-molecule Protein-Protein Interaction (PPI) dual inhibitors of Tumor Necrosis Factor (TNF) and Receptor Activator of NF-κB Ligand (RANKL).
    Melagraki G; Ntougkos E; Rinotas V; Papaneophytou C; Leonis G; Mavromoustakos T; Kontopidis G; Douni E; Afantitis A; Kollias G
    PLoS Comput Biol; 2017 Apr; 13(4):e1005372. PubMed ID: 28426652
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure-Based Discovery of Receptor Activator of Nuclear Factor-κB Ligand (RANKL)-Induced Osteoclastogenesis Inhibitors.
    Rinotas V; Liepouri F; Ouzouni MD; Chalkidi N; Papaneophytou C; Lampropoulou M; Vidali VP; Kontopidis G; Couladouros E; Eliopoulos E; Papakyriakou A; Douni E
    Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511048
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of Small-Molecules Targeting Receptor Activator of Nuclear Factor-κB Ligand (RANKL)-Receptor Activator of Nuclear Factor-κB (RANK) Protein-Protein Interaction by Structure-Based Virtual Screening and Hit Optimization.
    Jiang M; Peng L; Yang K; Wang T; Yan X; Jiang T; Xu J; Qi J; Zhou H; Qian N; Zhou Q; Chen B; Xu X; Deng L; Yang C
    J Med Chem; 2019 Jun; 62(11):5370-5381. PubMed ID: 31082234
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Porphyrin Derivatives Inhibit the Interaction between Receptor Activator of NF-κB and Its Ligand.
    Chypre M; Madel MB; Chaloin O; Blin-Wakkach C; Morice C; Mueller CG
    ChemMedChem; 2017 Oct; 12(20):1697-1702. PubMed ID: 28885764
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current Status and Future Prospects of Small-molecule Protein-protein Interaction (PPI) Inhibitors of Tumor Necrosis Factor (TNF) and Receptor Activator of NF-κB Ligand (RANKL).
    Melagraki G; Leonis G; Ntougkos E; Rinotas V; Papaneophytou C; Mavromoustakos T; Kontopidis G; Douni E; Kollias G; Afantitis A
    Curr Top Med Chem; 2018; 18(8):661-673. PubMed ID: 29875003
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure-based development of an osteoprotegerin-like glycopeptide that blocks RANKL/RANK interactions and reduces ovariectomy-induced bone loss in mice.
    Liu C; Chen X; Zhi X; Weng W; Li Q; Li X; Zou Y; Su J; Hu HG
    Eur J Med Chem; 2018 Feb; 145():661-672. PubMed ID: 29348072
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Caffeic acid 3,4-dihydroxy-phenethyl ester suppresses receptor activator of NF-κB ligand–induced osteoclastogenesis and prevents ovariectomy-induced bone loss through inhibition of mitogen-activated protein kinase/activator protein 1 and Ca2+–nuclear factor of activated T-cells cytoplasmic 1 signaling pathways.
    Wu X; Li Z; Yang Z; Zheng C; Jing J; Chen Y; Ye X; Lian X; Qiu W; Yang F; Tang J; Xiao J; Liu M; Luo J
    J Bone Miner Res; 2012 Jun; 27(6):1298-1308. PubMed ID: 22337253
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiosteoclastogenic activity of silicate-based materials antagonizing receptor activator for nuclear factor kappaB ligand-induced osteoclast differentiation of murine marcophages.
    Hung CJ; Kao CT; Chen YJ; Shie MY; Huang TH
    J Endod; 2013 Dec; 39(12):1557-61. PubMed ID: 24238446
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A RANKL G278R mutation causing osteopetrosis identifies a functional amino acid essential for trimer assembly in RANKL and TNF.
    Douni E; Rinotas V; Makrinou E; Zwerina J; Penninger JM; Eliopoulos E; Schett G; Kollias G
    Hum Mol Genet; 2012 Feb; 21(4):784-98. PubMed ID: 22068587
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rationally designed less toxic SPD-304 analogs and preliminary evaluation of their TNF inhibitory effects.
    Alexiou P; Papakyriakou A; Ntougkos E; Papaneophytou CP; Liepouri F; Mettou A; Katsoulis I; Maranti A; Tsiliouka K; Strongilos A; Chaitidou S; Douni E; Kontopidis G; Kollias G; Couladouros E; Eliopoulos E
    Arch Pharm (Weinheim); 2014 Nov; 347(11):798-805. PubMed ID: 25160057
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of diverse diterpenoid scaffolds from Euphorbia antiquorum and their activity against RANKL-induced osteoclastogenesis.
    Yin ZY; Dai Y; Hua P; Sun ZJ; Cheng YF; Yuan SH; Chen ZY; Gu Q
    Bioorg Chem; 2019 Nov; 92():103292. PubMed ID: 31561105
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aesculin modulates bone metabolism by suppressing receptor activator of NF-κB ligand (RANKL)-induced osteoclastogenesis and transduction signals.
    Zhao XL; Chen LF; Wang Z
    Biochem Biophys Res Commun; 2017 Jun; 488(1):15-21. PubMed ID: 28465233
    [TBL] [Abstract][Full Text] [Related]  

  • 14. N-Arylsulfonylsubstituted-1H indole derivatives as small molecule dual inhibitors of signal transducer and activator of transcription 3 (STAT3) and tubulin.
    Zhou Q; Zhu J; Chen J; Ji P; Qiao C
    Bioorg Med Chem; 2018 Jan; 26(1):96-106. PubMed ID: 29174507
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Licorice isoliquiritigenin suppresses RANKL-induced osteoclastogenesis in vitro and prevents inflammatory bone loss in vivo.
    Zhu L; Wei H; Wu Y; Yang S; Xiao L; Zhang J; Peng B
    Int J Biochem Cell Biol; 2012 Jul; 44(7):1139-52. PubMed ID: 22521613
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of 2,3'-diindolylmethanes as a novel class of PCSK9 modulators.
    Winston-McPherson GN; Xie H; Yang K; Li X; Shu D; Tang W
    Bioorg Med Chem Lett; 2019 Aug; 29(16):2345-2348. PubMed ID: 31227343
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Simvastatin, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, suppresses osteoclastogenesis induced by receptor activator of nuclear factor-kappaB ligand through modulation of NF-kappaB pathway.
    Ahn KS; Sethi G; Chaturvedi MM; Aggarwal BB
    Int J Cancer; 2008 Oct; 123(8):1733-40. PubMed ID: 18688862
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The naturally derived small compound Osthole inhibits osteoclastogenesis to prevent ovariectomy-induced bone loss in mice.
    Zhao D; Wang Q; Zhao Y; Zhang H; Sha N; Tang D; Liu S; Lu S; Shi Q; Zhang Y; Dong Y; Wang Y; Shu B
    Menopause; 2018 Dec; 25(12):1459-1469. PubMed ID: 29944638
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel tumor necrosis factor-α (TNF-α) inhibitors from small molecule library screening for their therapeutic activity profiles against rheumatoid arthritis using target-driven approaches and binary QSAR models.
    Zaka M; Abbasi BH; Durdagi S
    J Biomol Struct Dyn; 2019 Jun; 37(9):2464-2476. PubMed ID: 30047845
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of 1-Amino-4-(phenylamino)anthraquinone-2-sulfonate Sodium Derivatives as a New Class of Inhibitors of RANKL-Induced Osteoclastogenesis.
    Lee CC; Chen CL; Liu FL; Chiou CY; Chen TC; Wu CC; Sun WH; Chang DM; Huang HS
    Arch Pharm (Weinheim); 2016 May; 349(5):342-55. PubMed ID: 27071332
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.